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1King’s College London, Division of Cancer Studies, Cancer Epidemiology Group, Guy’s Hospital, 3rd Floor, Bermondsey Wing,
London SE1 9RT, UK; 2King’s College London, Division of Cancer Studies, Section of Research Oncology, London, UK; 3Guy’s and
St Thomas’ NHS Foundation Trust, London, UK; 4King’s College London, Division of Cancer Studies, Section of Cancer
Epidemiology and Population Health, London, UK; 5Regional Cancer Centre, Uppsala/O¨rebro, Uppsala, Sweden and
6Department of Surgical Sciences, Uppsala University, Uppsala, Sweden
Background: Studies comparing prognosis of breast cancer (BC) patients with and without locoregional recurrence (LR) present
conflicting results. We aimed to improve our understanding of the impact of LR on prognosis by examining a large cohort of
patients treated at Guy’s and St Thomas’ NHS Foundation Trust.
Methods: Risk factors associated with BC-specific death were investigated using Cox proportional hazards regression in 5199
women diagnosed between 1975 and 2007. Breast cancer-specific death following LR was assessed with Poisson regression.
Results: Overall, 552 women (11%) developed LR, with a median follow-up time of 4.28 years. Known factors associated with
BC-specific death (tumour stage, grade, and nodal status) were of significance in our data. Women with a shorter disease-free
interval had a worse prognosis. For instance, the HR for BC-specific death among women undergoing mastectomy with an LR
0.5–1 year after diagnosis of their primary tumour was 6.67 (95% CI: 3.71–11.99), when compared with women who did not
experience LR.
Conclusions: It often remains difficult to distinguish between a genuine LR and a new primary. The HRs for risk of BC-specific
death following a second lesion suggest that they may act as a marker of systemic disease, large tumour burden, or depleted host
defence. The clinically highly relevant impairment in prognosis calls for further research into the underlying mechanisms. We
showed that for at least 15 years of follow-up, the prognosis in women following the occurrence of an LR may benefit from careful
diagnostic and therapeutic management.
The influence of locoregional recurrences (LR) on the risk of breast
cancer progression is not fully understood (Halverson et al, 1992;
Willner et al, 1997; Koscielny and Tubiana, 1999; Elkhuizen et al,
2001; van Duijnhoven et al, 2011). Current evidence indicates
worse outcomes following LR (Halverson et al, 1992; Willner et al,
1997; Elkhuizen et al, 2001; van Duijnhoven et al, 2011) or a worse
prognosis associated only with specific LR tumour subtypes
(Koscielny and Tubiana, 1999). It has been suggested that a
shorter disease-free interval between the diagnosis of the primary
tumour and a second lesion is a determinant of poor prognosis
(Vicini et al, 2003; Komoike et al, 2006; Anderson et al, 2009;
Botteri et al, 2010; Vichapat et al, 2011; Tanis et al, 2012; van Laar
et al, 2013), and a short interval usually signals that distant
metastasis has already occurred (van der Sangen et al, 2013).
In one paper, the Early Breast Cancer Trialists Collaborative Group
(EBCTCG) showed that in up to 25% of cases LR was likely
*Correspondence: Dr M Van Hemelrijck; E-mail: mieke.vanhemelrijck@kcl.ac.uk
Received 3 February 2015; revised 15 July 2015; accepted 10 August 2015; published online 10 December 2015
& 2016 Cancer Research UK. All rights reserved 0007 – 0920/16
FULL PAPER
Keywords: breast cancer; recurrence; breast cancer-specific death
British Journal of Cancer (2016) 114, 88–95 | doi:10.1038/bjc.2015.314
88 www.bjcancer.com |DOI:10.1038/bjc.2015.314
associated with breast cancer death (Early Breast Cancer Trialists’
Collaborative G et al, 2011).
A model for the influence of metachronous contralateral breast
cancer on prognosis indicated that some studies may have
underestimated risk of death from contralateral tumours arising
close to the time of diagnosis of the primary tumour (Vichapat
et al, 2011). We applied a similar model to analyse breast cancer
prognosis after the occurrence of LR.
Using a hospital-based cohort of 567 women diagnosed with LR
and 4632 women who did not experience an LR, the current study
aimed to assess breast cancer-specific death while taking into
account LR as a time-dependent characteristic.
MATERIALS AND METHODS
Study population. From the Guy’s and St Thomas’ Breast Cancer
Tissue and Data Bank, a total of 5199 women were identified as
eligible for initial analysis as diagnosed with an invasive primary
breast cancer between 1st January 1975 and 31st December 2007 –
coded as C50 (based on ICD-10) in the Hospital’s Clinical Cancer
Database. Tissue samples and prospectively collected clinical data
on the diagnosis, treatment, and follow-up of all patients who were
diagnosed and/or treated within the Breast Clinic at Guy’s and St
Thomas’ NHS Trust were gathered. Trained data managers
manually enter the clinical and pathological data into the master
data set. For the purposes of this study, women with unknown
menopausal status were excluded (n¼ 202), as were those who
were pregnant and/or lactating (n¼ 14). Regional recurrences were
identified through patient reporting of symptoms and/or clinical
examination by a surgeon, and then confirmed using mammo-
graphy or ultrasound scans. Types of LR included were disease in
breast, ipsilateral axillary lymph nodes, internal mammary lymph
nodes, and skin recurrences. A secondary analysis was repeated
including only breast recurrences.
Table 1. Descriptive characteristics by locoregional
recurrence status, including women with a primary diagnosis
between the years of 1975 and 2007
Locoregional
recurrences
(N¼552)
No locoregional
recurrences
(N¼4502)
N(%) N(%)
Age at diagnosis (years)
p49 163 (31.59) 1206 (29.20)
50–59 156 (30.23) 1079 (26.13)
60–69 96 (18.60) 1019 (24.67)
X70 101 (19.57) 826 (20.00)
Mean follow-up (years)
Time from primary to death (s.d.) 10.35 (7.50) 12.16 (8.57)
Tumour side
Left 260 (47.10) 2267 (50.63)
Right 253 (45.83) 2094 (46.51)
Unknown 39 (7.07) 141 (3.13)
Menopausal status
Pre 200 (36.23) 1415 (31.43)
Peri 56 (10.14) 288 (6.40)
Post 296 (53.62) 2799 (62.17)
Family history
First degree 57 (10.33) 518 (11.51)
Second degree 38 (6.88) 306 (6.80)
None 417 (75.54) 3092 (68.68)
First and second degree 14 (2.54) 93 (2.07)
Third degree 0 (0.00) 21 (0.47)
Missing 26 (4.71) 472 (10.48)
No. of pregnancies
0 105 (22.11) 716 (22.16)
1–2 212 (44.63) 1395 (43.18)
3–4 118 (24.84) 855 (26.46)
44 39 (8.21) 243 (7.52)
Missing 1 (0.21) 22 (0.68)
Tumour size at diagnosis (cm)
o2 107 (19.38) 1507 (33.47)
2–3 144 (26.09) 1122 (24.92)
43 301 (54.53) 1873 (41.60)
Invasive grade
Grade 1 38 (6.70) 622 (13.43)
Grade 2 218 (38.45) 1724 (37.22)
Grade 3 202 (35.63) 1470 (31.74)
Missing 109 (11.78) 816 (17.62)
Invasive type
Ductal not otherwise specified 434 (78.62) 3580 (79.52)
Lobular 67 (12.14) 456 (10.13)
Other 5 (0.91) 72 (1.60)
Missing 46 (8.33) 394 (8.75)
Oestrogen receptor status
Negative 171 (30.98) 1052 (23.37)
Positive 330 (59.78) 3029 (67.28)
Missing 51 (9.24) 421 (9.35)
Progesterone receptor status
Negative 259 (46.92) 1709 (37.96)
Positive 230 (41.67) 2318 (51.49)
Missing 63 (11.41) 475 (10.55)
HER2 status
Negative 223 (40.40) 1970 (43.76)
Positive 70 (12.68) 525 (11.66)
Missing 259 (46.92) 2007 (44.58)
Operation type
Mastectomy 249 (45.11) 2487 (55.24)
Breast conservation 302 (54.71) 2011 (44.67)
Other surgery 1 (0.18) 4 (0.09)
Table 1. ( Continued )
Locoregional
recurrences
(N¼552)
No locoregional
recurrences
(N¼4502)
N(%) N(%)
Chemotherapy
No 438 (79.35) 3446 (76.54)
Yes 114 (20.65) 1056 (23.46)
Radiotherapy
No 299 (54.17) 2449 (54.40)
Yes 253 (45.83) 2053 (45.60)
Endocrine therapy
No 370 (67.03) 2599 (57.73)
Yes 182 (32.97) 1903 (42.27)
No. of examined lymph nodes
Mean (s.d.) 25.14 (8.71) 23.76 (8.99)
No. of positive lymph nodes
0 165 (29.89) 2076 (46.11)
1–3 153 (27.72) 1204 (26.74)
4–10 68 (12.32) 383 (8.51)
410 81 (14.67) 255 (5.66)
Missing 85 (15.40) 584 (19.97)
BC-specific death
Noa 190 (34.42) 3422 (76.01)
Yes 362 (65.58) 1080 (23.99)
Abbreviation: BC¼breast cancer.
aIncluding 242 for whom cause of death was unknown.
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Table 2. Multivariate HRs and 95% CI for risk of BC death by surgery type
Mastectomy Breast conservation
BC death
(N¼1168)
No BC death
(N¼1874) HR 95% CI
Death
(N¼656)
No BC death
(N¼2062) HR 95% CI
Locoregional recurrence
Yes 198 (16.95) 55 (2.93) 3.25 2.70–3.92 167 (25.46) 146 (7.08) 2.66 1.07–6.60
No 970 (83.05) 1819 (97.07) 1.00 Ref. 489 (74.54) 1916 (92.92) 1.00 Ref.
Mean age at diagnosis (years)
p49 311 (29.15) 469 (27.25) 1.00 Ref. 251 (41.08) 568 (29.88) 1.00 Ref.
50–59 354 (33.18) 379 (22.02) 1.34 1.12–1.59 153 (25.04) 537 (28.25) 0.85 0.66–1.09
60–69 253 (23.71) 474 (27.54) 0.96 0.79–1.17 92 (15.06) 416 (21.88) 0.78 0.57–1.06
X70 149 (13.96) 399 (23.18) 1.09 0.86–1.37 115 (18.82) 380 (19.99) 1.29 0.77–2.17
Invasive grade
Grade 1 51 (5.20) 234 (15.13) 1.00 Ref. 26 (4.58) 387 (22.46) 1.00 Ref.
Grade 2 465 (47.45) 716 (46.28) 1.53 1.25–1.87 263 (46.30) 716 (41.56) 2.48 1.78–3.46
Grade 3 460 (46.94) 568 (36.72) 2.15 1.75–2.63 274 (48.24) 570 (33.08) 3.66 2.63–5.10
Missing 4 (0.41) 29 (1.87) 0.76 0.28–2.06 5 (0.88) 50 (2.90) 0.92 0.29–2.97
No. of positive lymph nodes
0 303 (25.94) 991 (52.88) 1.00 Ref. 179 (27.29) 1000 (48.50) 1.00 Ref.
1–3 355 (30.39) 518 (27.64) 2.35 1.94–2.87 204 (31.10) 473 (22.94) 2.84 2.17–3.71
4–10 226 (19.35) 151 (8.06) 4.38 3.50–5.49 73 (11.13) 83 (4.03) 4.88 3.45–6.91
410 218 (18.66) 79 (4.22) 8.21 6.44–10.48 91 (13.87) 31 (1.50) 9.62 6.92–13.36
Missing 66 (5.65) 135 (7.20) 2.02 0.94–4.30 109 (16.62) 475 (23.040) 2.95 1.87–4.64
Chemotherapy
No 871 (74.57) 1505 (80.31) 1.00 Ref. 500 (76.22) 1554 (75.36) 1.00 Ref.
Yes 297 (25.43) 369 (19.69) 1.12 0.93–1.35 156 (23.78) 508 (24.64) 0.87 0.67–1.12
Radiotherapy
No 1013 (86.73) 1617 (86.29) 1.00 Ref. 103 (15.70) 377 (18.28) 1.00 Ref.
Yes 155 (13.27) 257 (13.71) 1.25 1.00–1.56 553 (84.30) 1685 (81.72) 0.60 0.37–0.98
Endocrine therapy
No 911 (78.00) 1258 (67.13) 1.00 Ref. 372 (56.71) 888 (43.06) 1.00 Ref.
Yes 257 (22.00) 616 (32.87) 0.78 0.65–0.93 284 (43.29) 1174 (56.94) 0.71 0.56–0.89
Interval between primary and LR
No LR 970 (83.05) 1819 (97.07) 1.00 Ref. 489 (74.54) 1916 (92.92) 1.00 Ref.
o0.5 22 (1.88) 2 (0.11) 10.56 7.42–15.03 7 (1.07) 3 (0.15) 5.19 1.18–22.91
0.5–1 41 (3.51) 6 (0.32) 8.10 5.98–10.97 26 (3.96) 12 (0.58) 11.21 4.12–30.47
1–2 51 (4.37) 10 (0.53) 5.65 4.40–7.26 29 (4.42) 18 (0.87) — —
2–5 55 (4.79) 13 (0.69) 5.07 4.02–6.40 57 (8.69) 48 (2.33) 4.72 1.67–13.33
5–10 19 (1.63) 12 (0.64) 3.25 2.27–4.66 38 (5.79) 34 (1.65) — —
410 9 (0.77) 12 (0.64) 1.62 0.97–2.68 10 (1.52) 31 (1.50) — —
Tumour side
Left 576 (49.32) 945 (50.43) 1.00 Ref. 306 (46.65) 1039 (50.39) 1.00 Ref.
Right 527 (45.12) 871 (46.48) 0.95 0.83–1.10 324 (49.39) 957 (46.41) 1.03 0.83–1.27
Unknown 65 (5.57) 58 (3.09) 1.47 0.65–3.29 26 (3.96) 66 (3.20) 1.32 0.54–4.21
Menopausal status
Pre 387 (33.13) 561 (29.94) 1.00 Ref. 274 (41.77) 670 (32.52) 1.00 Ref.
Peri 141 (12.07) 106 (5.66) 1.91 1.47–2.47 55 (8.38) 107 (5.19) 1.14 0.77–1.69
Post 640 (54.79) 1207 (64.41) 1.25 0.95–1.64 327 (49.85) 1283 (62.28) 0.72 0.49–1.07
Family history
First degree 132 (11.30) 233 (12.43) 1.00 Ref. 57 (8.69) 229 (11.11) 1.00 Ref.
Second degree 87 (7.45) 120 (6.40) 1.00 0.71–1.42 49 (7.47) 142 (6.89) 1.41 0.88–2.26
None 890 (76.20) 1327 (70.81) 1.04 0.84–1.30 500 (76.22) 1305 (63.29) 1.09 0.76–1.56
First and second degree 18 (1.54) 31 (1.65) 1.17 0.65–2.10 18 (2.74) 58 (2.81) 0.40 0.19–0.87
Third degree 0 (0.00) 9 (0.48) — — 1 (0.15) 11 (0.53) 2.23 0.30–16.40
Missing 41 (3.51) 154 (8.22) 0.95 0.62–1.44 31 (4.73) 317 (15.37) 0.40 0.19–0.83
No. of pregnancies
0 231 (21.67) 318 (22.44) 1.00 Ref. 112 (20.44) 292 (23.17) 1.00 Ref.
1–2 470 (43.54) 617 (43.54) 1.15 0.96–1.38 247 (45.07) 522 (41.43) 1.23 0.95–1.59
3–4 284 (25.83) 366 (25.83) 1.15 0.94–1.41 146 (26.64) 22 (25.56) 1.16 0.87–1.56
44 81 (7.60) 105 (7.41) 1.24 0.91–1.68 43 (7.85) 99 (7.86) 1.25 0.81–1.94
Missing 0 (0.00) 11 (0.78) — — 0 (0.00) 25 (1.98) — —
Tumour size (cm)
o2 135 (11.56) 403 (21.50) 1.00 Ref. 92 (14.02) 681 (33.03) 1.00 Ref.
2–3 279 (23.89) 559 (29.83) 1.21 0.93–1.59 236 (35.98) 764 (37.05) 2.18 1.52–3.12
43 754 (64.55) 912 (48.67) 1.84 1.44–2.35 328 (50.00) 617 (29.92) 3.33 2.34–4.73
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The following variables were retrieved from the clinical
database: age at diagnosis, period of initial diagnosis (1975–1979,
1980–1984, 1985–1989, 1990–1994, and after 1995), and tumour
characteristics (clinical size, pathological lymph node status,
histopathological type and grade, oestrogen and progesterone
receptor status), as well as treatment given for the initial cancer.
Follow-up information, including date of recurrence, date of last
contact, and cause of death, was obtained from medical records as
registered in the Hospital’s Clinical Cancer Database. Cause of
death was ascertained by national death certification obtained from
the National Cancer Registry (Table 1). All data collection was
carried out under NHS Research Ethics Committee approval
(REC Number: 12/EE/0493).
Statistical analysis. We assessed how known clinicodemographic
risk factors and LR effect risk of breast cancer-specific death using
Cox proportional hazards regression analysis. All analyses were
stratified by surgery type (mastectomy vs breast-conserving surgery
(BCS)). Where cause of death was unknown, women who
experienced distant metastases before death were considered to
have died of breast cancer.
To investigate how time between primary diagnosis and LR affects
breast cancer-specific death, we used LR as a time-varying covariate
in a Cox proportional hazards model. To graphically illustrate the
effect of time between primary diagnosis and LR on breast cancer-
specific death, we used Poisson regression. These models estimate
hazard curves for risk of breast cancer-specific death among women
with and without LR whereby follow-up time is split as (i) time
before development of LR and (ii) time after LR, using the logarithm
of time at risk as an offset. Risk of breast cancer-specific death for
women without LR was modelled through natural cubic splines with
knots in quartiles of time-to-event. Risk of breast cancer-specific
death for women with LR was similarly modelled through natural
cubic splines with knots in tertiles of time-to-event with two
additional restrictions: (i) risk of breast cancer-specific death because
of LR was bound to be zero at the onset of LR; (ii) additional risk
because of LR was bound not to be distinguished from the baseline
risk after 20 years of follow-up. The risk because of LR was allowed to
depend linearly on time between the two diagnoses.
These graphical analyses were not stratified by surgery type
because there is good evidence to suggest that BCS is a feasible
option for patients with tumours of up to 5 cm. Higher incidences of
LR have been reported in the longer term, but this does not appear
to influence prognosis (van Dongen et al, 2000; Litiere et al, 2012).
All analyses were performed using SAS software version 9.3.1
(SAS Institute Inc., Cary, NC) and R version 2.15.3 (R Foundation
for Statistical Computing, Vienna, Austria).
RESULTS
Demographics. Five hundred and sixty-seven women developed
LR without a prior distant metastasis. The median interval
between primary diagnosis and LR was 4.28 years (s.d. ±4.35).
There was no statistically significant difference in age at primary
diagnosis between women with (56.35 years (s.d. ±13.6))
and without LR (58.7 years (s.d.±12.1)). There was no difference
in family history of breast cancer between the two groups
(Table 1).
Risk of breast cancer death: entire study population. Table 2
shows that women with a shorter time interval to LR had
an increased risk of breast cancer-specific death compared
with women with a longer interval, (e.g., the HR for women
who underwent mastectomy in those who experienced an
LR within 6 months of primary diagnosis was 10.56 (95% CI:
7.42–15.03), whereas the HR for LR occurring 410 years
following primary diagnosis was 1.62 (95% CI: 0.97–2.68),
when compared with a reference group of women who did not
develop LR).
Risk of BC death–LR subgroup. A multivariate analysis looking
at the association between known clinicodemographic risk factors
and breast cancer-specific death (Table 2) was repeated in the
subgroup of women who experienced LR (Table 3). We observed
Table 2. ( Continued )
Mastectomy Breast conservation
BC death
(N¼1168)
No BC death
(N¼1874) HR 95% CI
Death
(N¼656)
No BC death
(N¼2062) HR 95% CI
Invasive type
Ductal Not otherwise
specified
921 (78.85) 1437 (76.68) 1.00 Ref. 559 (85.21) 1639 (79.49) 1.00 Ref.
Lobular 152 (13.01) 220 (11.74) 0.93 0.69–1.27 55 (8.38) 178 (8.63) 0.58 0.32–1.06
Other 10 (0.86) 28 (1.49) 0.56 0.21–1.51 8 (1.22) 41 (1.99) — —
Missing 85 (7.28) 189 (10.09) 1.40 0.72–2.71 34 (5.18) 204 (9.89) — —
Oestrogen receptor status
Negative 378 (32.50) 467 (24.92) 1.00 Ref. 216 (32.93) 365 (17.70) 1.00 Ref.
Positive 699 (59.55) 1221 (65.15) 0.81 0.69–0.95 406 (61.89) 1457 (70.66) 0.65 0.52–0.82
Missing 91 (7.95) 186 (9.93) 1.30 0.79–2.13 34 (5.18) 240 (11.64) 0.20 0.06–0.63
Progesterone receptor status
Negative 580 (49.66) 743 (39.65) 1.00 Ref. 310 (47.26) 648 (31.43) 1.00 Ref.
Positive 461 (39.47) 919 (49.04) 0.67 0.58–0.79 306 (46.65) 1169 (56.69) 0.76 0.61–0.94
Missing 127 (10.87) 212 (11.31) 1.37 0.99–1.89 40 (6.10) 245 (11.83) 0.29 0.12–0.70
HER2-status
Negative 459 (39.30) 732 (39.06) 1.00 Ref. 320 (48.78) 959 (46.51) 1.00 Ref.
Positive 174 (14.90) 205 (10.94) 1.37 1.11–1.70 106 (16.16) 196 (9.51) 1.67 1.26–2.22
Missing 535 (45.80) 937 (50.00) 0.83 0.70–0.97 230 (35.06) 907 (43.99) 0.76 0.60–0.98
Abbreviations: BC¼breast cancer; CI, confidence intervals; HR¼hazard ratios; LR¼ locoregional recurrence. —, no estimate because of small numbers. Models were adjusted for age, tumour
grade, pathological nodal stage, treatment methods of the initial cancer (except where stated), and locoregional recurrence as a time-dependent variable. The upper (above the heading
‘Tumour side’) section of the table represents a multivariable model including only covariates listed within this section. The following (below the heading ‘Tumour side’) section represents
models adjusted for all aforementioned variables.
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Table 3. Multivariate HRs and 95% CIs for risk of BC death following local recurrence by surgery type
Mastectomy Breast conservation
BC death
(N¼198)
No BC death
(N¼55) HR 95% CI
BC death
(N¼167)
No BC death
(N¼146) HR 95% CI
Mean age at diagnosis (years)
p49 49 (27.22) 12 (23.53) 1.00 Ref. 63 (39.38) 48 (34.78) 1.00 Ref.
50–59 67 (37.22) 18 (35.29) 0.95 0.66–1.38 39 (24.38) 33 (23.91) 1.18 0.76–1.81
60–69 46 (25.56) 14 (27.45) 0.65 0.43–0.98 19 (11.88) 18 (13.04) 1.52 0.84–2.74
X70 18 (10.00) 7 (13.73) 1.34 0.74–2.41 39 (24.38) 39 (28.26) 2.89 0.93–8.93
Invasive grade
Grade 1 9 (5.56) 7 (18.42) 1.00 Ref. 4 (2.86) 18 (15.13) 1.00 Ref.
Grade 2 71 (43.83) 15 (39.47) 2.76 1.36–5.59 68 (48.57) 64 (53.78) 4.49 1.40–14.42
Grade 3 82 (50.62) 16 (42.11) 3.90 1.89–8.02 67 (47.86) 36 (30.25) 7.21 2.23–23.36
Missing 0 (0.00) 0 (0.00) — — 1 (0.71) 1 (0.84) — —
No. of positive lymph nodes
0 37 (18.69) 22 (40.00) 1.00 Ref. 44 (26.35) 67 (45.89) 1.00 Ref.
1–3 54 (27.27) 16 (29.09) 1.21 0.76–1.92 52 (31.14) 36 (24.66) 2.01 1.29–3.13
4–10 45 (22.73) 6 (10.91) 1.96 1.19–3.23 15 (8.98) 3 (2.05) 3.23 1.72–6.08
410 47 (23.74) 4 (7.27) 2.41 1.44–4.05 26 (15.57) 3 (2.05) 3.69 2.16–6.29
Missing 15 (7.58) 7 (12.73) 1.24 0.60–2.55 30 (17.96) 37 (25.34) 1.68 0.98–2.90
Chemotherapy
No 148 (74.75) 45 (81.82) 1.00 Ref. 132 (79.04) 124 (84.93) 1.00 Ref.
Yes 50 (25.25) 10 (18.18) 1.40 0.98–1.99 35 (20.96) 22 (15.07) 1.51 0.91–2.50
Radiotherapy
No 177 (89.39) 48 (87.27) 1.00 Ref. 37 (22.16) 41 (28.08) 1.00 Ref.
Yes 21 (10.61) 7 (12.73) 1.39 0.77–2.50 130 (77.84) 105 (71.92) 1.30 0.69–2.46
Endocrine therapy
No 162 (81.82) 43 (78.18) 1.00 Ref. 102 (61.08) 72 (49.32) 1.00 Ref.
Yes 36 (18.18) 12 (21.82) 0.70 0.43–1.15 65 (38.92) 74 (50.68) 0.65 0.38–1.12
Time to LR (years)
Mean (s.d.) 2.75 (3.08) 5.64 (4.76) 0.81 0.76–0.86 3.74 (3.09) 6.47 (5.69) 0.80 0.75–0.86
o0.5 22 (11.11) 2 (3.64) 24.92 10.29–60.38 7 (4.19) 3 (2.05) 8.78 2.59–29.73
0.5–1 41 (20.71) 6 (10.91) 11.96 5.28–27.13 26 (15.57) 12 (8.22) 29.21 12.34–69.11
1–2 51 (25.76) 10 (18.18) 8.03 3.67–17.57 29 (17.37) 18 (12.33) 7.21 3.33–15.61
2–5 56 (28.28) 13 (23.64) 5.42 2.51–11.69 57 (34.13) 48 (32.88) 3.93 1.94–7.98
5–10 19 (9.60) 12 (21.82) 2.71 1.16–6.37 38 (22.75) 34 (23.39) 2.80 1.33–5.86
410 9 (4.55) 12 (21.82) 1.00 (ref) 10 (5.99) 31 (21.23) 1.00 (ref)
Tumour side
Left 97 (48.99) 27 (49.09) 1.00 Ref. 72 (43.11) 69 (47.26) 1.00 Ref.
Right 86 (43.43) 21 (38.18) 1.26 0.92–1.74 89 (53.29) 64 (43.84) 1.19 0.83–1.68
Unknown 15 (7.58) 7 (12.73) 3.24 0.43–24.51 6 (3.59) 13 (8.90) 20.40 2.52–164.98
Menopausal status
Pre 65 (32.83) 15 (27.27) 1.00 Ref. 70 (41.92) 59 (40.69) 1.00 Ref.
Peri 28 (14.14) 8 (14.55) 1.34 0.80–2.24 11 (6.59) 9 (6.21) 1.50 0.74–3.03
Post 105 (53.03) 32 (58.18) 1.26 0.69–2.32 86 (51.50) 77 (53.10) 1.57 0.83–2.97
Family history
First degree 23 (11.62) 11 (20.00) 1.00 Ref. 12 (7.19) 12 (8.22) 1.00 Ref.
Second degree 19 (9.60) 5 (9.09) 2.59 1.27–5.27 5 (2.99) 11 (7.53) 0.71 0.24–2.09
None 149 (75.25) 34 (61.82) 1.77 1.11–2.82 137 (82.04) 105 (71.92) 1.00 0.53–1.90
First and second degree 3 (1.52) 3 (5.45) 1.23 0.35–4.26 6 (3.59) 3 (2.05) 0.56 0.16–1.95
Missing 4 (2.02) 2 (3.64) 9.58 2.91–31.48 7 (4.19) 15 (10.27) 1.06 0.30–3.73
No.of pregnancies
0 46 (25.00) 11 (21.57) 1.00 Ref. 28 (19.86) 25 (22.73) 1.00 Ref.
1–2 84 (45.65) 24 (47.06) 0.67 0.46–0.98 68 (48.23) 40 (36.36) 0.95 0.62–1.46
3–4 44 (23.91) 11 (21.57) 0.75 0.48–1.17 35 (24.82) 28 (25.45) 0.69 0.40–1.20
44 10 (5.43) 4 (7.84) 0.71 0.34–1.48 10 (7.09) 16 (14.55) 0.55 0.27–1.12
Missing 0 (0.00) 1 (1.96) — — 0 (0.00) 1 (0.91) — —
Tumour size (cm)
o2 20 (10.10) 5 (9.09) 1.00 Ref. 27 (16.17) 28 (19.18) 1.00 Ref.
2–3 46 (23.23) 15 (27.27) 1.11 0.58–2.11 56 (33.53) 55 (37.67) 0.90 0.53–1.55
43 132 (66.67) 35 (63.64) 1.34 0.74–2.42 84 (50.30) 63 (43.15) 1.15 0.69–1.90
Invasive type
Ductal Not otherwise Specified 154 (77.78) 34 (61.82) 1.00 Ref. 141 (84.43) 116 (79.45) 1.00 Ref.
lobular 26 (13.13) 14 (25.45) 0.62 0.30–1.27 15 (8.98) 12 (8.22) 0.50 0.20–1.25
Other 1 (0.51) 0 (0.00) 8.87 1.09–72.42 3 (1.80) 2 (1.37) 3.35 0.35–32.17
Missing 17 (8.59) 7 (12.73) 2.19 0.43–11.18 8 (4.79) 16 (10.96) 0.69 0.17–2.79
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decreased risk of BC-specific death as the time interval between
primary tumour and LR increased. For instance, the HR for LRs
occurring within 6 months of the primary tumour was 13.76 (95%
CI: 7.08–26.74), when compared with a reference group where LRs
occurred 45 years following primary diagnosis in women who
underwent mastectomy.
Figure 1 demonstrates a sharp increase in the hazard
of breast cancer-specific death for women diagnosed with LR
soon after diagnosis of their primary breast tumour relative to
later occurring LRs, as observed in the HRs (Table 3).
The magnitude of this hazard declines continuously with time,
but does not return to that of the level of women not
experiencing an LR, even 20 years after the diagnosis of their
primary diagnosis. These curves were replicated by year of
primary diagnosis (1975–1989 and 1990–2007), by surgery type,
and for breast recurrences only; all patterns remained consistent
(Figure A1 in Appendix).
DISCUSSION
Women with LR had a considerably poorer prognosis with regard
to breast cancer-specific death compared with those without LR,
especially if the LR occurred close in time to primary diagnosis.
The increase in risk after LR was still apparent 20 years
postprimary diagnosis and at no point in time declined to the
level of risk in women without LR at the corresponding time of
follow-up.
Some studies reported a worse prognosis for women with LR
compared with those without (Willner et al, 1997; Elkhuizen et al,
2001), whereas others found a similar prognosis for women with
and without LR (Robinson et al, 1993). One study showed a 2-year
survival of 53% following an LR, compared with 86% among non-
relapsed women (Willner et al, 1997). A further study found that
patients who experienced an LR within 2 years of BCS were at
especially high risk of distant metastasis and breast cancer-specific
death (Elkhuizen et al, 2001).
Although the cited studies have touched on the possible effect of
time interval, our study benefits from both long-term and complete
follow-up allowing for a more in-depth and precise investigation
into the importance of the timing of the LR. In our study, short
interval time was the strongest determinant of risk for breast
cancer-specific death following LR. The increased elevation of the
hazard ratio for LR closer in time to primary tumour may suggest
that a rapidly occurring LR may be an indication of an undetected
existing distant disease. This is also supported by the fact that
women with a shorter interval time often rapidly develop
metastasis after LR (Macmillan et al, 1996; Elkhuizen et al, 2001;
Komoike et al, 2006).
Our findings combined with existing literature may indicate that
the decline in risk of breast cancer-specific death following LR as
the time interval increases could be because of a proportion of
these tumours being second primaries, as opposed to genuinely
recurring, active disease (Holmberg et al, 1988; Hartman et al,
2007). A proportion of the second primaries should be localised
disease with a chance to cure – and especially so if the women were
under regular mammography surveillance. Later occurring LR may
also be less aggressive recurrences, as opposed to rapidly growing
Table 3. ( Continued )
Mastectomy Breast conservation
BC death
(N¼198)
No BC death
(N¼55) HR 95% CI
BC death
(N¼167)
No BC death
(N¼146) HR 95% CI
Oestrogen receptor status
Negative 71 (35.86) 14 (25.45) 1.00 Ref. 62 (37.13) 27 (18.49) 1.00 Ref.
Positive 110 (55.56) 31 (56.36) 0.79 0.57–1.09 97 (58.08) 101 (69.18) 0.54 0.38–0.78
Missing 17 (8.59) 10 (18.18) 0.31 0.08–1.29 8 (4.79) 18 (12.33) 0.63 0.19–2.08
Progesterone receptor status
Negative 108 (54.55) 21 (38.13) 1.00 Ref. 86 (51.50) 49 (33.56) 1.00 Ref.
Positive 67 (33.84) 21 (38.13) 0.78 0.56–1.09 71 (42.51) 79 (54.11) 0.63 0.44–0.91
Missing 23 (11.62) 13 (23.64) 0.45 0.21–0.99 10 (5.99) 18 (12.33) 1.01 0.36–2.87
HER2-status
Negative 75 (37.88) 16 (29.09) 1.00 Ref. 79 (47.31) 57 (39.04) 1.00 Ref.
Positive 30 (15.15) 4 (7.27) 1.31 0.83–2.07 26 (15.57) 12 (8.22) 1.37 0.83–2.27
Missing 93 (46.97) 35 (63.64) 0.59 0.41–0.84 62 (37.13) 77 (52.74) 0.69 0.47–1.03
Abbreviations: BC¼breast cancer; CI, confidence interval; HR¼hazard ratios; LR¼ locoregional recurrence; Ref.¼ reference. —, No estimate because of small numbers. Models were adjusted
for age, tumour grade, pathological nodal stage, treatment methods of the initial cancer (except where stated), and locoregional recurrence as a time-dependent variable. The upper (above
part heading ‘Tumour side’) section of the table represents a multivariable model including only covariates listed within this section. The following (from part heading ‘Tumour side’) section
represents models adjusted for all aforementioned variables.
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Figure 1. Estimated hazards of breast cancer death from Poisson
regression model. The blue curve represents the hazard of breast
cancer death for women without recurrence. The dark red, bright red,
dark orange, light orange, yellow, and black curves represent the
hazard of breast cancer death for local recurrence diagnosed at
different interval times (0.5, 1, 2, 5, 10, and 15 years). There were 5194
women who did not experience a locoregional recurrence (LR) (blue
line), 34 women experienced LRs within 6 months, 85 women within 1
year, 108 women between 1 and 2 years, 174 women within 2–5 years,
103 women between 5 and 10 years, and finally, 62 women
experienced LRs between 10 and 15 years following their primary
diagnosis.
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lesions. Another plausible explanation for the association between
the interval and breast cancer-specific death is that two tumours
occurring close in time indicate a depleted host defence mechanism
(von Mensdorff-Pouilly et al, 2000; de Visser et al, 2006).
Strengths and limitations. A strength of our study is the long-
term and complete follow-up of a cohort of breast cancer patients,
in which it was possible to measure breast cancer-specific survival.
However, there are limitations that should be addressed.
Histopathological tumour size was not available for all patients,
and clinically assessed tumour size was used in its place. Although
this measurement is less accurate, it did allow for a further way in
which to rank patients by disease severity. Information on the
tumour characteristics of LR were not included, and thus we are
unable to infer the significance of their contribution towards
prognosis. Furthermore, we could not use the characteristics of the
primary and the LR to distinguish true recurrences from second
primaries. We have no reason to believe that the treatment
protocol at Guy’s & St Thomas’ NHS Trust was different or in any
way responsible for the higher estimates observed here of risk of
breast cancer death following an LR compared with those observed
in previous studies. Finally, additional information on treatment
adherence and comorbidities may have confounded our observa-
tions. However, as all women were treated in the same Unit in the
same Hospital, we are confident that we have included high-quality
treatment data.
CONCLUSION
It remains difficult to distinguish between an LR and a new
primary. However, our results of an increased risk of breast cancer-
death after an LR/new primary suggest that LR acts as a marker of
systemic disease, large tumour burden, or depleted host defence
and that the interpretation of this marker varies with interval to the
primary lesion. The clinically highly relevant impairment in
prognosis calls for further research into the underlying mechan-
isms, and indicates that for at least a 15-year follow-up the
occurrence of an LR, a careful diagnostic and therapeutic
management, is needed to improve the prognosis of affected
women. These data further informs the design of post-treatment
surveillance programs.
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Figure A1. Estimated hazards of breast cancer death from Poisson regression model in (A) women diagnosed between 1975 and 1990 and
(B) women diagnosed between 1990 and 2007. The blue curve represents the hazard of breast cancer death for women without recurrence. The
dark red, bright red, dark orange, light orange, yellow, and black curves represent the hazard of breast cancer death for local recurrence diagnosed
at different interval times (0.5, 1, 2, 5, 10, and 15 years). A full color version of this figure is available at British Journal of Cancer online.
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